Literature DB >> 24323472

Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.

Cristina Jiménez-Ortigosa1, Padmaja Paderu, Mary R Motyl, David S Perlin.   

Abstract

MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of β-(1,3)-glucan. We evaluated the in vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene(s) of Candida spp. and Aspergillus spp. MK-3118 demonstrated enhanced efficacy for most C. albicans and C. glabrata ER isolates relative to caspofungin, with decreased MICs and half-maximal inhibitory concentrations (IC50s).

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24323472      PMCID： PMC3910825          DOI： 10.1128/AAC.02145-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors.

Authors:  J Onishi; M Meinz; J Thompson; J Curotto; S Dreikorn; M Rosenbach; C Douglas; G Abruzzo; A Flattery; L Kong; A Cabello; F Vicente; F Pelaez; M T Diez; I Martin; G Bills; R Giacobbe; A Dombrowski; R Schwartz; S Morris; G Harris; A Tsipouras; K Wilson; M B Kurtz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Serum differentially alters the antifungal properties of echinocandin drugs.

Authors:  Padmaja Paderu; Guillermo Garcia-Effron; Sergey Balashov; Guillaume Delmas; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-04-09       Impact factor: 5.191

Review 3.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

4.  Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

Authors:  R Hajdu; R Thompson; J G Sundelof; B A Pelak; F A Bouffard; J F Dropinski; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

6.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

7.  In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods.

Authors:  Michael A Pfaller; Shawn A Messer; Mary R Motyl; Ronald N Jones; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

8.  Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.

Authors:  Guillermo Garcia-Effron; Samuel Lee; Steven Park; John D Cleary; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

9.  Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST).

Authors:  Michael A Pfaller; Shawn A Messer; Mary R Motyl; Ronald N Jones; Mariana Castanheira
Journal:  J Antimicrob Chemother       Date:  2012-11-28       Impact factor: 5.790

10.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079
View more
  37 in total

Review 1.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model.

Authors:  Annie Lee; Brendan Prideaux; Matthew Zimmerman; Claire Carter; Stephen Barat; David Angulo; Véronique Dartois; David S Perlin; Yanan Zhao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 3.  New facets of antifungal therapy.

Authors:  Ya-Lin Chang; Shang-Jie Yu; Joseph Heitman; Melanie Wellington; Ying-Lien Chen
Journal:  Virulence       Date:  2016-11-07       Impact factor: 5.882

4.  In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris.

Authors:  Elizabeth L Berkow; David Angulo; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

5.  De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance.

Authors:  Cristina Jiménez-Ortigosa; Winder B Perez; David Angulo; Katyna Borroto-Esoda; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie Jaramillo; Marcos Olivo; Jason Pizzini; Gabriel Catano; Thomas F Patterson
Journal:  J Antimicrob Chemother       Date:  2018-02-01       Impact factor: 5.790

7.  Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species.

Authors:  Wiley A Schell; A M Jones; Katyna Borroto-Esoda; Barbara D Alexander
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 8.  Drugs in Clinical Development for Fungal Infections.

Authors:  Maria F Gonzalez-Lara; Jose Sifuentes-Osornio; Luis Ostrosky-Zeichner
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

9.  Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.

Authors:  Michael A Pfaller; Shawn A Messer; Paul R Rhomberg; Katyna Borroto-Esoda; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

10.  Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates.

Authors:  Frédéric Lamoth; Barbara D Alexander
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.